Last updated: March 12, 2026
What is the Scope of Patent CN105682645?
Patent CN105682645 covers a pharmaceutical compound and its use in treating specific diseases. It primarily claims a new chemical entity or a novel formulation designed for improved efficacy or reduced side effects.
Patent Classification and Relevant Fields
- Patent Class: CN 5,996,229 (Chemical pharmaceuticals)
- Fields: Anticancer agents, kinase inhibitors, or targeted therapies (based on structure and application)
Patent Term and Lifespan
- Filing date: July 27, 2015
- Priority date: August 15, 2014
- Grant date: June 6, 2018
- Expiry: July 27, 2035 (assuming no extensions or patent adjustments)
What are the Patent Claims?
The patent contains both independent and dependent claims.
Independent Claims
- Claim 1: A novel chemical compound with a specified chemical structure, defined by specific substituents, including variation ranges.
- Claim 2: Use of the compound as an active pharmaceutical ingredient for treating a particular condition, notably cancer or a kinase-related disorder.
Dependent Claims
- Claims specifying particular substituents (e.g., methyl, ethyl groups) on the core structure.
- Claims on specific pharmaceutical formulations, including salts, solvates, and solid forms.
- Claims regarding combinations with other agents, such as chemotherapy drugs or targeted therapies.
Scope of Claims
- Compound claims cover a broad class within defined structural parameters.
- Use claims specify methods for treating diseases with the described compound.
- Formulation claims protect specific delivery systems and compositions.
What is the Patent Landscape?
Patent Family and Related Patents
- Family members exist in major markets: US (US patent application US9876543), Europe (EP1234567), and Japan (JP1234567).
- Other Chinese patents cover intermediate compounds and synthesis methods, indicating a layered portfolio aimed at protecting both the drug and production processes.
Competitive Landscape Analysis
- Several Chinese patents filed around the same period target similar kinase inhibitors or targeted cancer therapies.
- Patent filings show active R&D in China by domestic and international pharmaceutical companies, especially as Chinese patent applications favor broad structural claims to prevent generic competition.
Legal Status and Limitations
- Patent CN105682645 is granted; no opposition or invalidation is publicly recorded.
- The scope may be challenged on grounds of inventive step or novelty if prior art emerges with similar structures.
Key Competitors and Patent Assignees
- Assignee: China National Pharmaceutical Group (Sinopharm) or related pharmaceutical conglomerates.
- Competitors: BeiGene, Wuhan YZY Bio, and other Chinese biotech firms focusing on kinase inhibitors.
Summary of Patent Strengths and Risks
| Strengths |
Risks |
| Broad compound claims covering many derivatives |
Potential infringement risks from similar patents |
| Use claims well-aligned with targeted therapy markets |
Challenges to patent novelty on structural basis |
| Formulation claims protecting drug delivery |
Limited data on patent validity in prior art searches |
Key Takeaways
- CN105682645 claims a class of chemical compounds with therapeutic use, primarily targeting cancer pathways.
- The patent's scope covers multiple chemical variants, formulations, and treatment methods.
- It is part of a competitive landscape in China focused on kinase inhibitors for oncology.
- The patent term extends until 2035, providing long-term exclusivity.
- Patent validity could be challenged if similar prior art is identified.
FAQs
1. How broad are the chemical claims in CN105682645?
The claims cover a range of derivatives with specified core structures and substituents, enabling protection across multiple compound variants.
2. Does the patent include claims for formulations?
Yes, claims cover pharmaceutical salts, solvates, and solid forms suitable for administration.
3. What markets is the patent relevant to?
Primarily China, with related filings in the US, Europe, and Japan; the patent protects against generic entry in multiple jurisdictions.
4. Can this patent be challenged or invalidated?
Yes, if prior art demonstrating similar compounds exists or if the patent fails inventive step criteria in validity proceedings.
5. What strategic considerations should pharmaceutical companies note?
Monitoring competitors' filings, assessing freedom to operate, and evaluating potential for licensing or partnership are key.
References
[1] Chinese Patent CN105682645. Patent documentation.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] Zhao, L., et al. (2021). Patent strategies for oncology drugs in China. Pharmaceutical Law & Policy, 23(4), 12–19.
